MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Developmental Drug Helps Protect Against Radiation Damage

By MedImaging International staff writers
Posted on 19 May 2009
Print article
A drug currently under development has been shown to protect cells from the damaging effects of radiation exposure, a new study suggests.

The findings of the study were presented at the 100th annual meeting of the American Association for Cancer Research (AACR), April 18-22, 2009, in Denver, CO, USA. The study, led by Joel Greenberger, M.D., professor and chairman of the department of radiation Oncology at the University of Pittsburgh School of Medicine (Pitt; PA, USA), is overseen by Pitt's Center for Medical Countermeasures Against Radiation. The center is dedicated to identifying and developing small molecule radiation protectors and mitigators that can be easily accessed and administered in the event of a large-scale radiological or nuclear emergency.

JP4-039, the new developmental drug assists mitochondria, the energy generator of all cells, in combating irradiation-induced cell death. For this study, cells treated immediately after irradiation with JP4-039 demonstrated significant radioprotection, suggesting a potential role for the drug as a mitigator of radiation damage.

"Currently, no drugs on the market counteract the effects of radiation exposure,” said Dr. Greenberger. "We know this drug can counteract the damage caused by irradiation, and now we want to develop the ideal dosage, one that is effective for the general population while remaining nontoxic. Our goal is to take this drug through a phase I clinical trial, and once the dosage is established, develop the drug for late-stage clinical trials and market licensing.”

This study was funded by the Biomedical Advanced Research and Development Authority (BARDA), U.S. Department of Health and Human Services (Washington, DC, USA). In 2008, BARDA awarded Dr. Greenberger and members of his lab US$2.7 million to help develop a radiation mitigator drug that could counteract the effects of radiation exposure in case of large-scale public exposure. The ultimate goal of the contract is to develop an easily administered drug that the Centers for Disease Control and Prevention in the Department of Health and Human Services can store and fly to hospitals and care facilities if and when an emergency occurs.

Related Links:
University of Pittsburgh School of Medicine
Biomedical Advanced Research and Development Authority
Centers for Disease Control and Prevention

Multi-Use Ultrasound Table
Clinton
Ultra-Flat DR Detector
meX+1717SCC
Diagnostic Ultrasound System
MS1700C
Digital Radiographic System
OMNERA 300M

Print article

Channels

MRI

view channel
Image: Comparison showing 3T and 7T scans for the same participant (Photo courtesy of P Simon Jones/University of Cambridge)

Ultra-Powerful MRI Scans Enable Life-Changing Surgery in Treatment-Resistant Epileptic Patients

Approximately 360,000 individuals in the UK suffer from focal epilepsy, a condition in which seizures spread from one part of the brain. Around a third of these patients experience persistent seizures... Read more

Ultrasound

view channel
Image: The new type of Sonogenetic EchoBack-CAR T cell (Photo courtesy of Longwei Liu/USC)

Smart Ultrasound-Activated Immune Cells Destroy Cancer Cells for Extended Periods

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a highly promising cancer treatment, especially for bloodborne cancers like leukemia. This highly personalized therapy involves extracting... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more